EC
CMPX icon

EntryPoint Capital’s Compass Therapeutics CMPX Stock Holding History

EntryPoint Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,265
Closed -$155K – 813
2026
Q1 		$155K Buy
29,265
+16,102
+122% +$92.9K 0.05% 674
2025
Q4 		$70.7K Buy
+13,163
New +$60.8K 0.03% 622

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EntryPoint Capital's CMPX Position: Q2 2026 in Review

EntryPoint Capital sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 29,265 shares — an estimated $155K sold.

EntryPoint Capital first reported a position in CMPX in Q4 2025 and held it in 2 quarters. The position peaked at $155K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • EntryPoint Capital reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 29,265 Compass Therapeutics shares in Q2 2026, an estimated $155K.
  • EntryPoint Capital first reported a position in Compass Therapeutics in Q4 2025 and held it in 2 quarters.
  • EntryPoint Capital's Compass Therapeutics position peaked at $155K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.